Anbio Biotechnology Strengthens Board Oversight With Appointment of Michael Zhang as Audit Committee Chair

Anbio Biotechnology Class A ( (NNNN) ) has provided an update.

Effective January 21, 2026, Anbio Biotechnology appointed Michael Zhang, a finance professional with more than 30 years’ experience and managing partner at Healthcare Alpha Management since 2014, as a director, chair of the audit committee, and member of both the nominating and compensation committees, replacing Kenneth Li, whose departure was stated not to be due to any disagreement with the company’s operations, policies, or procedures. The board determined that Zhang is an independent director and an audit committee financial expert under U.S. securities and Nasdaq rules, and his appointment, governed by a director offer letter providing annual compensation of $30,000 and standard confidentiality, non-solicitation, and D&O insurance protections, is expected to strengthen Anbio’s board oversight and financial governance without signaling internal dispute or strategic disruption for shareholders and other stakeholders.

More about Anbio Biotechnology Class A

Anbio Biotechnology, a Cayman Islands-incorporated company with principal executive offices in Frankfurt, Germany, is a foreign private issuer listed on Nasdaq, operating in the biotechnology and healthcare sector. The company is subject to U.S. securities regulation for foreign issuers and maintains standard board committee structures, including audit, nominating, and compensation committees, consistent with Nasdaq corporate governance requirements.

Average Trading Volume: 34,552

Technical Sentiment Signal: Strong Buy

Current Market Cap: $4.33B

For an in-depth examination of NNNN stock, go to TipRanks’ Overview page.